CPI-97545
US: Bristol-Myers Squibb wins antitrust approval to buy Celgene
Bristol-Myers Squibb (BMS) and Celgene have won US antitrust approval for their merger on the condition that they sell Celgene’s psoriasis drug Otezla, reported Reuters. Bristol-Myers Squibb stated the decision meant it had all the needed regulatory approvals and would close the acquisition on Wednesday, November 20. Amgen has agreed to buy Celgene’s Otezla business, […]
Featured News
Justice Department Backs xAI in Environmental Lawsuit Over Mississippi Data Center
Jun 16, 2026 by
CPI
National Security Concerns Are Shaping AI Infrastructure Development
Jun 16, 2026 by
CPI
Colorado Refines, Rather Than Retreats From, AI Regulation
Jun 16, 2026 by
CPI
Canada Opens Broad Antitrust Investigation Into Food Supply Chain Amid Cost Concerns
Jun 16, 2026 by
CPI
Ballard Spahr Strengthens Antitrust Bench as Competition Work Intensifies
Jun 16, 2026 by
CPI
Antitrust Mix
Antitrust Chronicle® – (Geo)Political Antitrust
May 28, 2026 by
CPI
Competition Policy in Turbulent Geopolitical Times
May 28, 2026 by
Christophe Carugati & Annabelle Gawer
The New Political Determinants of U.S. Antitrust Policy
May 28, 2026 by
Aziz Z. Huq
The Geopolitical Rewiring of Antitrust
May 28, 2026 by
Hayane C. Dahmen
Three Strikes Against Political Antitrust
May 28, 2026 by
Nolan McCarty & Sepehr Shahshahani